SS
UBX

SBI Securities’s Unity Biotechnology UBX Stock Holding History

SBI Securities’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,834
Closed -$1.86K – 4317
2025
Q2 		$1.86K Buy
4,834
+915
+23% +$784 ﹤0.01% 2416
2025
Q1 		$4.08K Buy
3,919
+557
+17% +$1.01K ﹤0.01% 1977
2024
Q4 		$3.28K Buy
+3,362
New +$4.18K ﹤0.01% 2091

Other funds holding UBX

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
AIP
Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return
AWM
AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

SBI Securities's UBX Position: Q3 2025 in Review

SBI Securities sold out of Unity Biotechnology (UBX) in Q3 2025, closing a stake of 4,834 shares — an estimated $1.86K sold.

SBI Securities first reported a position in UBX in Q4 2024 and held it in 3 quarters. The position peaked at $4.08K in Q1 2025. 6 funds tracked by Wall St. Rank hold UBX as of Q3 2025.

  • SBI Securities reported no remaining Unity Biotechnology position as of Q3 2025 after selling out during the quarter.
  • SBI Securities sold 4,834 Unity Biotechnology shares in Q3 2025, an estimated $1.86K.
  • SBI Securities first reported a position in Unity Biotechnology in Q4 2024 and held it in 3 quarters.
  • SBI Securities's Unity Biotechnology position peaked at $4.08K in Q1 2025.
  • 6 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2025.

Based on SBI Securities's 13F filing for Q3 2025, filed 5 Nov 2025.